GH
GH
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
71 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
GH has an insider buy conviction of 50%, compared to the Unknown sector buy average of 20%. GH ranks #235 in insider activity out of 270 tracked companies in its industry.
Multiple Insiders
S - Sale Insiders
$24.49M total
Over the last 90 days, corporate insiders at GH (GH) engaged in a total of 71 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for GH shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 40.8K shares valued at $24.49M on Jun 15, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering GH and the Unknown sector.
The Impact of Interest Rates on Insider Behavior: A Macro Analysis
When the Fed tightens, equity valuations fall, but insider purchase activity does not always follow the same pattern. This report examines three rate-hike cycles to show how rising rates affect the frequency and conviction of C-suite stock buys.
Institutional Ownership vs. Insider Trading: Understanding the Data Flow
High institutional ownership reduces information asymmetry, but does it also reduce the predictive power of insider trades? This analysis tests whether stocks with more than 70% institutional ownership show weaker Form 4 signal performance.
Legal vs. Illegal Insider Trading: Setting the Record Straight
The line between legal and illegal insider trading is narrower than most investors realize. This explainer covers the material non-public information standard, the Misappropriation Theory, and how regulators reconstruct trading chronologies.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
FAQs About GH Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for GH.